For research and educational purposes only. Not medical advice.

Tesamorelin Reference

Educational, not medical advice reference for Tesamorelin: Fat Loss, GH Release; regulatory status, evidence posture, source review, and schedule notes. Also…

Reference summary

This entry displays only Egrifta WR label-reference fields. It does not approve or describe research-vial tesamorelin protocols.

Categories
Fat Loss, GH Release
Aliases
Egrifta WR, Growth hormone-releasing factor analog
Evidence posture
human
Regulatory status
FDA-approved label reference exists for Egrifta WR to reduce excess abdominal fat in HIV-infected adults with lipodystrophy; it is not indicated for weight-loss management.
Content review status
label verified

Selected public sources